Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blinded, Randomized, Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265 is registered in ClinicalTrials.gov with Croma-Pharma GmbH as lead sponsor.

NCT NCT04763265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04763265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blinded, Randomized, Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
Lead sponsor
Croma-Pharma GmbH
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2020
Completion date
February 1, 2021
Enrollment
208 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

frown lines